Show simple item record

Files in this item

Thumbnail

Item metadata

dc.contributor.authorZeissler, Marie-Louise
dc.contributor.authorEastwood, Jordan
dc.contributor.authorMcCorry, Kieran
dc.contributor.authorHanemann, C. Oliver
dc.contributor.authorZajicek, John P.
dc.contributor.authorCarroll, Camille B.
dc.date.accessioned2016-08-16T13:30:14Z
dc.date.available2016-08-16T13:30:14Z
dc.date.issued2016-06-27
dc.identifier245056815
dc.identifieree73e0bf-c110-4a21-bce0-ed29e7cdd607
dc.identifier84979895378
dc.identifier000385402300134
dc.identifier.citationZeissler , M-L , Eastwood , J , McCorry , K , Hanemann , C O , Zajicek , J P & Carroll , C B 2016 , ' Delta-9-tetrahydrocannabinol protects against MPP + toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesis ' , Oncotarget , vol. 7 , no. 29 , pp. 46603-46614 . https://doi.org/10.18632/oncotarget.10314en
dc.identifier.issn1949-2553
dc.identifier.otherORCID: /0000-0003-3481-825X/work/64034690
dc.identifier.urihttps://hdl.handle.net/10023/9313
dc.descriptionThis project was supported through a studentship awarded by the Plymouth University Peninsula Schools of Medicine and Dentistry.en
dc.description.abstractProliferator-activated receptor γ (PPARγ) activation can result in transcription of proteins involved in oxidative stress defence and mitochondrial biogenesis which could rescue mitochondrial dysfunction in Parkinson's disease (PD).The PPARγ agonist pioglitazone is protective in models of PD; however side effects have limited its clinical use. The cannabinoid Δ9-tetrahydrocannabinol (Δ9-THC) may have PPARγ dependent anti-oxidant properties. Here we investigate the effects of Δ9-THC and pioglitazone on mitochondrial biogenesis and oxidative stress. Differentiated SH-SY5Y neuroblastoma cells were exposed to the PD relevant mitochondrial complex 1 inhibitor 1-methyl- 4-phenylpyridinium iodide (MPP+). We found that only Δ9-THC was able to restore mitochondrial content in MPP+ treated SH-SY5Y cells in a PPARγ dependent manner by increasing expression of the PPARγ co-activator 1a (PGC-1a), the mitochondrial transcription factor (TFAM) as well as mitochondrial DNA content. Co-application of Δ9- THC with pioglitazone further increased the neuroprotection against MPP+ toxicity as compared to pioglitazone treatment alone. Furthermore, using lentiviral knock down of the PPARγ receptor we showed that, unlike pioglitazone, Δ9-THC resulted in a PPARγ dependent reduction of MPP+ induced oxidative stress. We therefore suggest that, in contrast to pioglitazone, Δ9-THC mediates neuroprotection via PPARγ-dependent restoration of mitochondrial content which may be beneficial for PD treatment.
dc.format.extent12
dc.format.extent2214358
dc.language.isoeng
dc.relation.ispartofOncotargeten
dc.subjectMitochondrial biogenesisen
dc.subjectMPP+en
dc.subjectParkinson's diseaseen
dc.subjectPeroxisome proliferator-activated receptoren
dc.subjectΔ9-tetrahydrocannabinolen
dc.subjectRC0254 Neoplasms. Tumors. Oncology (including Cancer)en
dc.subjectOncologyen
dc.subjectNDASen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subject.lccRC0254en
dc.titleDelta-9-tetrahydrocannabinol protects against MPP+ toxicity in SH-SY5Y cells by restoring proteins involved in mitochondrial biogenesisen
dc.typeJournal articleen
dc.contributor.institutionUniversity of St Andrews. School of Medicineen
dc.identifier.doi10.18632/oncotarget.10314
dc.description.statusPeer revieweden
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=84979895378&partnerID=8YFLogxKen


This item appears in the following Collection(s)

Show simple item record